Epoetin Hospira

BIOLOGICAL5 trials

Sponsors

Hospira, now a wholly owned subsidiary of Pfizer, Pfizer

Conditions

Chronic Kidney DiseaseChronic Renal FailureChronic Renal Failure Requiring Hemodialysis

Phase 1

A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

CompletedNCT01170078

Hospira, now a wholly owned subsidiary of PfizerChronic Renal Failure

Start: 2010-07-31End: 2011-01-31Updated: 2017-03-20

Phase 3

A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

CompletedNCT01473407

PfizerChronic Kidney Disease, Chronic Renal Failure

Start: 2012-01-31End: 2014-02-11Updated: 2018-09-10

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

CompletedNCT01473420

PfizerChronic Kidney Disease, Chronic Renal Failure

Start: 2012-01-17End: 2014-02-28Updated: 2018-08-09

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

CompletedNCT01628120

PfizerChronic Renal Failure Requiring Hemodialysis

Start: 2012-05-31End: 2015-02-13Updated: 2019-03-18

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

CompletedNCT01628107

PfizerChronic Renal Failure Requiring Hemodialysis

Start: 2012-07-16End: 2015-01-02Updated: 2018-07-19

Related Papers

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies.

2019-08-281 citations